Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nice Ltd

133.38
+1.401.06%
Post-market: 133.37-0.0100-0.01%19:57 EST
Volume:1.41M
Turnover:187.25M
Market Cap:8.24B
PE:15.96
High:135.40
Open:128.35
Low:128.35
Close:131.98
52wk High:193.52
52wk Low:122.94
Shares:61.74M
Float Shares:61.40M
Volume Ratio:1.40
T/O Rate:2.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.36
EPS(LYR):6.97
ROE:14.92%
ROA:7.28%
PB:2.21
PE(LYR):19.13

Loading ...

NiCE Likely to See Limited Near-Term Growth, RBC Says

MT Newswires Live
·
Yesterday

NICE Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 14

Northland Securities Reaffirms Their Buy Rating on NICE (NICE)

TIPRANKS
·
Nov 14

D.A. Davidson Remains a Hold on NICE (NICE)

TIPRANKS
·
Nov 14

NICE (NICE) Receives a Hold from Cantor Fitzgerald

TIPRANKS
·
Nov 14

NICE (NICE) Gets a Buy from RBC Capital

TIPRANKS
·
Nov 14

Nice Ltd : Citigroup Raises Target Price to $211 From $209

THOMSON REUTERS
·
Nov 14

Strong Q3 Performance and Promising Outlook Drive Buy Rating for NICE

TIPRANKS
·
Nov 14

Analysts’ Top Technology Picks: CommVault Systems (CVLT), NICE (NICE)

TIPRANKS
·
Nov 14

Stock Track | NICE Ltd Soars 9.30% on Strong Q3 Results and AI-Driven Growth

Stock Track
·
Nov 14

Stock Track | NICE Ltd Soars 9.30% on Strong Q3 Results and AI-Driven Growth

Stock Track
·
Nov 14

NICE Just Showed Why Its AI-First Strategy Is Winning

Benzinga
·
Nov 13

Stock Track | NICE Ltd Soars 6.23% Pre-market on Strong Q3 Results and Raised Guidance

Stock Track
·
Nov 13

NiCE Q3 Non-GAAP Earnings, Revenue Rise; Annual Outlook Updated -- Shares Up Pre-Bell

MT Newswires Live
·
Nov 13

Israeli cloud-based software provider NICE posts higher Q3 cloud revenue on AI demand

Reuters
·
Nov 13

GUIDANCE: (NICE) NiCE Expects 2025 Adjusted EPS Range $12.18 to $12.32, vs. FactSet Est of $12.98

MT Newswires Live
·
Nov 13

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

GlobeNewswire
·
Nov 06

UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment

Benzinga
·
Oct 18

NICE Price Target Announced at $152.00/Share by Jefferies

Dow Jones
·
Oct 13

Nice resinstated with a Hold at Jefferies

TIPRANKS
·
Oct 13